#endometrial cancer

Can Some Women With Endometrial Cancer Forgo Radiation After Surgery?

One project led by Bradley Corr, MD, uses the ORIEN resource to gather data on a specific mutation of endometrial cancer recurrence.

The virtual intervention was deemed appropriate and involved an acceptable time commitment.

The clinical trial used a combo of Verzenio and Femara in patients with recurrent endometrial cancer that’s estrogen receptor positive.

New data show 46,000 cancer cases could be prevented each year if Americans exercised least 5 hours each week.

Data from early clinical trials suggest new precision cancer treatments are on the horizon.

The immunotherapy is now approved to treat tumors with a specific genetic mutation anywhere in the body.

New checkpoint inhibitor Jemperli is approved for cancers with deficient mismatch repair mechanism for fixing damaged DNA.

IUDs were even more effective at preventing endometrial cancer in women with a precancerous condition.

Using birth control correlates to a small increase in breast cancer risk but a larger, permanent drop in ovarian and endometrial cancer.

Keytruda can treat women whose endometrial cancer cells have certain characteristics.

Adagrasib targets a specific cancer-causing mutation, while VS-6766 interferes with multiple steps in a cell growth signaling pathway.

Women who took this drug in addition to standard chemotherapy lived longer than those who just received standard chemo.

Cancer Health spoke with the Foundation for Women’s Cancer about gynecologic cancer education, prevention and eradication.

A consortium of health providers and researchers hopes to raise public awareness of how exercise can benefit those living with cancer.

Keytruda plus Lenvima is first approval under Project Orbis collaboration.

Some of the most common and deadly cancers receive little attention and resources.